Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.79 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145685 | 1.00 | NPC1 (0.79) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL13497007 | 0.85 | POLB (1.00) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL21145748 | 0.83 | MEN1 (0.70) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL21145672 | 0.83 | KMT2A (0.76) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL21145673 | 0.83 | KMT2A (0.76) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL21145750 | 0.83 | MEN1 (0.70) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL13497014 | 0.82 | NPC1 (0.72) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL21192742 | 0.82 | MEN1 (0.78) | NPC1RAB9AKLF5KMT2AMEN1 | |
| SCHEMBL21145664 | 0.80 | KMT2A (0.78) | NPC1RAB9AKLF5POLBKMT2A | |
| SCHEMBL21145666 | 0.80 | KMT2A (0.78) | NPC1RAB9AKLF5POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | NPC1 1570/4885RAB9A 2636/4885KLF5 4547/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | NPC1 1570/4885RAB9A 2636/4885KLF5 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.